| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/18/2008 | US7344870 3-phosphoinositide-dependent protein kinase |
| 03/18/2008 | US7344861 Nucleotide sequences coding protein factors for use in identifying modulators for diagnosis, treatment and prevention of cell proliferative, metabolic, inflammatory, nervous system and immune disorders |
| 03/18/2008 | US7344858 Glycosylated human granulocyte colony-stimulating factor (G-CSF) isoform |
| 03/18/2008 | US7344846 Diagnostics and therapeutics for macular degeneration-related disorders |
| 03/18/2008 | US7344844 Can be used for the treatment of diabetes or for delaying the onset of diabetes |
| 03/18/2008 | US7344843 Identifying modulators of transmembrane protein (PROLIXIN) for use in prevention and treatment of hyperlipidemia, athersclerosis, insulin resistance, diabetes and hypertension |
| 03/18/2008 | US7344829 Methods for detecting the efficacy of anticancer treatments |
| 03/18/2008 | US7344734 Controlling particle size; antiagglomerant |
| 03/18/2008 | US7344724 proteins and genes codes, used for medical diagnosis, screening biological targets and as vaccines against gramnegative bacterial infections |
| 03/18/2008 | US7344721 Polypeptide for the treatment of cancer and a method for preparation thereof |
| 03/18/2008 | US7344719 Homologous 28-kilodalton immunodominant protein genes of Ehrlichia canis and uses thereof |
| 03/18/2008 | US7344717 Use of erythropoietin in the treatment of rheumatoid arthritis |
| 03/18/2008 | US7344716 Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
| 03/18/2008 | US7344713 Decreased fat absorption with an anti-lipase antibody |
| 03/18/2008 | US7344709 Administering interferon-beta (IFN- beta 9), after failed treatment with interferon- alpha |
| 03/18/2008 | US7344699 Drug conjugate comprising an erythropoietin receptor ligand and an anticancer agent |
| 03/18/2008 | CA2329128C Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| 03/18/2008 | CA2328955C Fetal testing for prediction of low birth weight |
| 03/18/2008 | CA2320430C Recombinant mistletoe lectins |
| 03/18/2008 | CA2316908C Method of producing elastin, elastin-based biomaterials and tropoelastin materials |
| 03/18/2008 | CA2315395C Compositions and methods for treatment of alopecia |
| 03/18/2008 | CA2264739C Inhibition of nuclear transcription factor nf-kb by caffeic acid phenethyl ester (cape), derivatives of cape, capsaicin (8-methyl-n-vanillyl-6-nonenamide) and resiniferatoxin |
| 03/18/2008 | CA2258878C Liposomal influenza vaccine composition and method |
| 03/18/2008 | CA2189145C Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent |
| 03/18/2008 | CA2185043C Monoclonal antibodies recognizing tie-receptor and their use |
| 03/18/2008 | CA2181073C Tissue-specific enhancer active in prostate |
| 03/18/2008 | CA2167980C Cgrp antagonist used in a cosmetic composition; pharmaceutical or dermatologic composition produced |
| 03/18/2008 | CA2166102C Redirection of cellular immunity by receptor chimeras |
| 03/18/2008 | CA2154982C Preparation of .alpha.1 antichymotrypsin |
| 03/18/2008 | CA2089735C Ryegrass pollen allergen |
| 03/18/2008 | CA2015060C Novel antibody delivery system for biological response modifiers |
| 03/13/2008 | WO2008031098A1 Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
| 03/13/2008 | WO2008031016A2 Heterocyclic ligands for integrin imaging and therapy |
| 03/13/2008 | WO2008031009A2 Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders |
| 03/13/2008 | WO2008030988A2 Selectively targeted antimicrobial peptides and the use thereof |
| 03/13/2008 | WO2008030968A2 Fusion peptide therapeutic compositions |
| 03/13/2008 | WO2008030539A2 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
| 03/13/2008 | WO2008030283A1 Methods of diagnosing and treating complications of pregnancy |
| 03/13/2008 | WO2008030265A2 Combination pressure therapy |
| 03/13/2008 | WO2008029897A1 Endotoxin absorbent for preventing or treating autoimmune disease |
| 03/13/2008 | WO2008029871A1 Nerve fiber degeneration inhibitor |
| 03/13/2008 | WO2008029868A1 Ocular fibrous neovascularization inhibitor |
| 03/13/2008 | WO2008029807A1 Novel polypeptide having cytotoxicity against cancer, method for screening for the polypeptide, and use of the polypeptide |
| 03/13/2008 | WO2008029601A1 Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient |
| 03/13/2008 | WO2008029565A1 Compound having inhibitory activity on histone deacetylase, and pharmaceutical comprising the compound as active ingredient |
| 03/13/2008 | WO2008029493A1 Nerve fiber degeneration inhibitor |
| 03/13/2008 | WO2008029189A1 Regulation of expression of p140cap protein in tumors |
| 03/13/2008 | WO2008029169A2 Method of treating respiratory disorders |
| 03/13/2008 | WO2008029167A1 Method of treating peripheral nerve disorders |
| 03/13/2008 | WO2008028965A2 Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof |
| 03/13/2008 | WO2008028963A2 Calreticulin for its use as a medication for the treatment of cancer in a mammal |
| 03/13/2008 | WO2008028928A1 Novel combination of agents for the treatment of hiv-associated adipose redistribution syndrome (hars) |
| 03/13/2008 | WO2008028888A2 Use of cripto-1 or cripto-3 for the treatment of skeletal muscle wasting |
| 03/13/2008 | WO2008028684A2 Peptides with high affinity for the prolactin receptor |
| 03/13/2008 | WO2008028645A1 Peptides binding the tpo receptor |
| 03/13/2008 | WO2008028530A1 Compounds as aptamer-dimers and their uses in diagnosis and therapy |
| 03/13/2008 | WO2008028497A1 A composition of egg white copper complexes with medicinal benifits |
| 03/13/2008 | WO2008028405A1 Neukinase, a downstream protein of neuregulin |
| 03/13/2008 | WO2008028251A1 Dna-binding protein, nucleoprotein complex and method of use |
| 03/13/2008 | WO2008028250A1 Therapeutic agents, targets and diagnostics |
| 03/13/2008 | WO2008014252A3 Iap inhibitors |
| 03/13/2008 | WO2008001113A3 Use of wnt5a for inhibiting scarring |
| 03/13/2008 | WO2007149406A9 Modified coagulation factor ix polypeptides and use thereof for treatment |
| 03/13/2008 | WO2007147590A3 Solution and method to reduce, treat and/or prevent oxidative stress and cell activation |
| 03/13/2008 | WO2007136752A3 Erythropoietin compositions |
| 03/13/2008 | WO2007136738A3 Novel hydrophilic polymers as medical lubricants and gels |
| 03/13/2008 | WO2007133711B1 Pharmaceutical compositions for vein irritating drugs |
| 03/13/2008 | WO2007132445A8 Use of non-catalytic form of heparanase and peptides thereof for reversing the anti-coagulant effects of heparinoids |
| 03/13/2008 | WO2007128896A3 Protease inhibitor compound, notably papain, cathepsin k and cathepsin b, and a procedure for the purification of protease inhibitor molecules |
| 03/13/2008 | WO2007126365A3 Further medical uses of antisecretory protein |
| 03/13/2008 | WO2007126363A3 Antisecretory protein for use in the treatment of compartment syndrome |
| 03/13/2008 | WO2007116428A3 Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis |
| 03/13/2008 | WO2007113540A3 Regulating fat and carbohydrate oxidation in muscle tissue comprising controlling carnitine content in muscle |
| 03/13/2008 | WO2007100568A3 T cell receptors and related materials and methods of use |
| 03/13/2008 | WO2007095583A3 Methods for treating cancer and sensitizing cancer cells using the serine protease inhibitor, maspin |
| 03/13/2008 | WO2007053574A3 Combinations comprising sorafenib and interferon for the treatment of cancer |
| 03/13/2008 | WO2007047998A3 Mutations and polymorphisms of hdac2 |
| 03/13/2008 | WO2005010153A3 Antibodies and uses thereof |
| 03/13/2008 | US20080064998 Chitosan biomaterial frozen in aqueous solution to form a frozen chitosan structure from which water is removed forming a sponge-like structure; adhesion strength and resistance to dissolution in high blood flow bleeding situations |
| 03/13/2008 | US20080064859 Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| 03/13/2008 | US20080064857 Immunoglobulin for use in diagnosis, prevention and treatment of metabolic disorders of pancreas |
| 03/13/2008 | US20080064854 Composition of a polypeptide and an amphiphilic compound in an ionic complex and the use thereof |
| 03/13/2008 | US20080064853 Nervous system protein for use in treatment and prevention of nervous system and seizure disorders |
| 03/13/2008 | US20080064764 Isolated nucleic acids; antibody for selective binding; biodrug treating osteoporosis, osteoblast, bone disorders, osteocalcin mediated disorder |
| 03/13/2008 | US20080064676 Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity |
| 03/13/2008 | US20080064660 Modulation of Inflammation Related to Columnar Epithelia |
| 03/13/2008 | US20080064651 A 21-base antisense oligonucleotide which inhibits gene expression of testosterone-repressed prostate message-2 by tumor cells; prostate and renal cell cancer; enhanced chemosensitivity, hormone and radiation sensitivities |
| 03/13/2008 | US20080064647 A polyvalent multimeric complex formed from a plurality of circularly permuted chimeric pRNA molecules, each carrying a stabilized biologically active moiety; degradation resistant stabilized ribozyme is correctly folded such that it remains intracellularly active |
| 03/13/2008 | US20080064644 Serum-Free Cell Culture Medium for Mammalian Cells |
| 03/13/2008 | US20080064643 Peptidomimetic antagonists prevent signalling interference of the TLR/IL-R1 receptor system; antiinflammatory agents; autoimmune diseases; cardiovascular and atherogenic diseases; sepsis and shock; transplant rejection |
| 03/13/2008 | US20080064642 Excellent receptivity, pharmacokinetics, enzyme resistance with capability to significantly prevent and treat conditions wherein BKB1Rs are induced and over-expressed |
| 03/13/2008 | US20080064641 Thr-ala-leu-arg-ile-arg-ala-thr-tyr-gly-glu-tyr, a fragment of the gamma 2 chain of laminin 5, has high biopermeability therough the epidermis and increases cellular adhesion; increases skin aging and wrinkle resistance, elasticity, healing, vascularization; cosmetics |
| 03/13/2008 | US20080064640 Particularly drugs and cosmetic agents; ethoxylated meadowform oil having between 10 and 19 ethoxy units, and the delivered agent, especially analgesics, antiinflammatory agents or antiwrinkle agents; improved penetration and bioavailability |
| 03/13/2008 | US20080064639 Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis |
| 03/13/2008 | US20080064638 Proteins related to schizophrenia and uses thereof |
| 03/13/2008 | US20080064637 Before cardiopulmonary bypass surgery or coronary artery bypass grafting; injecting a polypeptide preferential inhibitor of kallikrein, rather than aprotinin |
| 03/13/2008 | US20080064636 Modification of Feeding Behaviour |
| 03/13/2008 | US20080064635 Whey protein concentrate containing docosahexaenoic acid, arachidonic acid and other fatty acids |
| 03/13/2008 | US20080064634 Disintegrin and microtubule stabilizing agent (small molecule cell division inhibitor); preventing metastasis |
| 03/13/2008 | US20080064633 Preventing fibronectin deposition and fibrosis; phospholipase A2 inhibition; cystic fibrosis |